Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. (Q48204088)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 November 2016

Language	Label	Description	Also known as
English	Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.	scientific article published on 22 November 2016

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

multiple sclerosis

0 references

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Luca Prosperini

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Antonio Cortese

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Serena Ruggieri

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Giancarlo Di Battista

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Massimiliano Mirabella

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

author name string

Francesco Saccà

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Cinzia Cordioli

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Fabio Buttari

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Simona Pontecorvo

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Assunta Bianco

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Shalom Haggiag

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Vincenzo Brescia Morra

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Ruggero Capra

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Elisabetta Ferraro

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Ada Francia

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Simonetta Galgani

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Claudio Gasperini

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Enrico Millefiorini

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Carlo Pozzilli

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

publication date

22 November 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Journal of Neurology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

264

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

284-294

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

https://scigraph.springernature.com/pub.10.1007/s00415-016-8343-5

0 references

Multiple sclerosis-a quiet revolution

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Comparative efficacy of switching to natalizumab in active multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Matched cohort methods for injury research

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Basic methods for sensitivity analysis of biases.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Reporting treatment outcomes in observational data: A fine balance.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

The changing face of multiple sclerosis clinical trial populations

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Review of methodological issues of clinical trials in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8343-5

21 January 2018

Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27878443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group—Italian Neurological Society

1 reference

https://pubmed.ncbi.nlm.nih.gov/27878443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic "matrix design"

1 reference

https://pubmed.ncbi.nlm.nih.gov/27878443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27878443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

observational studies: propensity score analysis of non-randomized data.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27878443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27878443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00415-016-8343-5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27878443%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48204088&oldid=1456988472"